Patents by Inventor Mark J. Kurth

Mark J. Kurth has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CFTR REGULATORS AND METHODS OF USE THEREOF
    Publication number: 20210347742
    Abstract: Provided herein are compounds that activate CFTR and methods for treating constipation, dry eye disorders, and other diseases and disorders.
    Type: Application
    Filed: April 8, 2021
    Publication date: November 11, 2021
    Inventors: Alan S. Verkman, Marc H. Levin, Onur Cil, Mark J. Kurth
  • CFTR regulators and methods of use thereof
    Patent number: 11084795
    Abstract: Provided herein are compounds that activate CFTR and methods for treating constipation, dry eye disorders, and other diseases and disorders.
    Type: Grant
    Filed: December 23, 2016
    Date of Patent: August 10, 2021
    Assignee: The Regents of the University of California
    Inventors: Alan S. Verkman, Marc H. Levin, Onur Cil, Mark J. Kurth
  • CFTR REGULATORS AND METHODS OF USE THEREOF
    Publication number: 20190031622
    Abstract: Provided herein are compounds that activate CFTR and methods for treating constipation, dry eye disorders, and other diseases and disorders.
    Type: Application
    Filed: December 23, 2016
    Publication date: January 31, 2019
    Inventors: Alan S. Verkman, Marc H. Levin, Onur Cil, Mark J. Kurth
  • Cyanoquinoline compounds having activity in correcting mutant-CFTR processing and increasing ion transport and uses thereof
    Patent number: 9073863
    Abstract: The present disclosure provides pharmaceutical compositions, pharmaceutical preparations and methods for increasing activity of a mutant cystic fibrosis transmembrane conductance regulator protein (mutant-CFTR). The pharmaceutical compositions, pharmaceutical preparations and methods are useful for the study and treatment of disorders associated with mutant-CFTR, such as cystic fibrosis. The pharmaceutical compositions and pharmaceutical preparations may include one or more cyanoquinoline-containing compounds of the embodiments, or an analog or derivative thereof.
    Type: Grant
    Filed: May 25, 2012
    Date of Patent: July 7, 2015
    Assignee: The Regents of the University of California
    Inventors: Alan S. Verkman, Puay-Wah Phuan, Mark J. Kurth, John Knapp
  • Cyanoquinoline Compounds Having Activity in Correcting Mutant-Cftr Processing and Increasing Ion Transport and Uses Thereof
    Publication number: 20140296215
    Abstract: The present disclosure provides pharmaceutical compositions, pharmaceutical preparations and methods for increasing activity of a mutant cystic fibrosis transmembrane conductance regulator protein (mutant-CFTR). The pharmaceutical compositions, pharmaceutical preparations and methods are useful for the study and treatment of disorders associated with mutant-CFTR, such as cystic fibrosis. The pharmaceutical compositions and pharmaceutical preparations may include one or more cyanoquinoline-containing compounds of the embodiments, or an analog or derivative thereof.
    Type: Application
    Filed: May 25, 2012
    Publication date: October 2, 2014
    Applicant: The Regents of the University of California
    Inventors: Alan S. Verkman, Puay-Wah Phuan, Mark J. Kurth, John Knapp
  • Heterocyclic ligands for integrin imaging and therapy
    Patent number: 8486370
    Abstract: The present invention provides ?4?1 integrin ligands that display high binding affinity, specificity, and stability. The ligands comprise a peptide having n independently selected amino acids, wherein at least one amino acid is an unnatural amino acid or a D-amino acid, and wherein n is an integer of from 3 to 20. Methods are provided for administering the ligands for treating cancer, inflammatory diseases, and autoimmune diseases. Also provided are methods for administering the ligands for imaging a tumor, organ, or tissue in a subject.
    Type: Grant
    Filed: September 7, 2007
    Date of Patent: July 16, 2013
    Assignee: The Regents of the University of California
    Inventors: Richard D. Carpenter, Mirela Andrei, Ruiwu Liu, Kit S. Lam, Mark J. Kurth
  • Compounds having activity in correcting mutant-CFTR processing and uses thereof
    Patent number: 8389736
    Abstract: The invention provides compositions, pharmaceutical preparations and methods for increasing activity of a mutant cystic fibrosis transmembrane conductance regulator protein (mutant-CFTR). The compositions pharmaceutical preparations and methods are useful for the study and treatment of disorders associated with mutant-CFTR, such as cystic fibrosis. The compositions and pharmaceutical preparations of the invention may comprise one or more bithiazole-containing compounds of the invention, or an analog or derivative thereof.
    Type: Grant
    Filed: September 5, 2008
    Date of Patent: March 5, 2013
    Assignee: The Regents of the University of California
    Inventors: Mark J. Kurth, Alan S. Verkman
  • Heterocyclic Ligands for Integrin Imaging and Therapy
    Publication number: 20100310455
    Abstract: The present invention provides ?4?1 integrin ligands that display high binding affinity, specificity, and stability. The ligands comprise a peptide having n independently selected amino acids, wherein at least one amino acid is an unnatural amino acid or a D-amino acid, and wherein n is an integer of from 3 to 20. Methods are provided for administering the ligands for treating cancer, inflammatory diseases, and autoimmune diseases. Also provided are methods for administering the ligands for imaging a tumor, organ, or tissue in a subject.
    Type: Application
    Filed: September 7, 2007
    Publication date: December 9, 2010
    Applicant: The Regents of The University of California
    Inventors: Richard D. Carpenter, Mirela Andrei, Ruiwu Liu, Kit S. Lam, Mark J. Kurth
  • Compounds Having Activity in Correcting Mutant-CFTR Processing and Uses Thereof
    Publication number: 20100273839
    Abstract: The invention provides compositions, pharmaceutical preparations and methods for increasing activity of a mutant cystic fibrosis transmembrane conductance regulator protein (mutant-CFTR). The compositions pharmaceutical preparations and methods are useful for the study and treatment of disorders associated with mutant-CFTR, such as cystic fibrosis. The compositions and pharmaceutical preparations of the invention may comprise one or more bithiazole-containing compounds of the invention, or an analog or derivative thereof.
    Type: Application
    Filed: September 5, 2008
    Publication date: October 28, 2010
    Inventors: Mark J. Kurth, Alan S. Verkman